A new report by a nonprofit health group finds vaccines could prevent the spread of the pandemic and reduce the number of cases in the United States.
The Chikunya Vaccine Collaborative, a nonprofit that helps promote the vaccine, released a report Thursday saying it had obtained a second-hand review of the first batch of vaccine, which has been given to about 8,000 people in the U.S. to help develop the first-generation vaccines.
The report said the second-generation Chikuneya vaccine, in development at Pfizer Inc., could protect up to 50 percent of people in developed countries, and the vaccine could reduce the spread and transmission of the disease to about 20 percent of the world population.
The vaccine is expected to be available for the U, U.K., Canada, Australia, New Zealand and South Africa in 2021.
It was developed by Pfizer and Sanofi Pasteur.
In a statement Thursday, Pfizer said the vaccine is safe and effective for humans and is “among the most widely used vaccines in the world.”
“While we have yet to see a clear proof-of-concept clinical trial with Chikwangunya vaccines, we are hopeful that the findings of the new Chikuno-Pfizer clinical trial will pave the way for a broader and more rigorous safety trial for the Chikunsunya Phase IIa vaccine,” Pfizer spokeswoman Melissa McGlashan said.
“We continue to be committed to advancing our vaccines to more patients as quickly as possible.”
Pfizers vaccine, a second generation of the Chikkunya and Chikyangunya, is currently in clinical trials and is scheduled for commercial release in 2021 and 2024.
The first Chikyu-PfuChikwangy vaccines were released in 2012.
Pfizer did not provide an additional financial statement.